Lung cancer: Future directions

Respirology

Volumn 12, Issue 4, 2007, Pages 471-477

  Lam, Wah K ^a   Watkins, D Neil ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Biological therapy; Gene profiling test; Lung cancer; Molecular diagnosis; Targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; BORTEZOMIB; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IMATINIB; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; NAVELBINE; PACLITAXEL; PEMETREXED; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RIBONUCLEOTIDE REDUCTASE;

BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CANCER RISK; CANCER STAGING; CLINICAL RESEARCH; DNA FINGERPRINTING; EARLY DIAGNOSIS; GENETIC SUSCEPTIBILITY; HUMAN; INDIVIDUALIZATION; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NAUSEA; NEPHROTOXICITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; STEM CELL; SYSTEMATIC REVIEW; TREATMENT PLANNING; VOMITING;

CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CHEMOTHERAPY, ADJUVANT; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; NEOPLASM STAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK ASSESSMENT; TUMOR STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34250761346     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2007.01105.x     Document Type: Review

References (67)

1. Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer Cell 2002 1 : 49 52.
2. Schwartz AG. Lung cancer: family history matters. Chest 2006 130 : 936 7.
3. Amos CI, Xu W, Spitz MR. Is there a genetic basis for lung cancer susceptibility? Recent Results Cancer Res. 1999 151 : 3 12.
4. Bailey-Wilson JE, Amos CI, Pinney SM, Petersen GM, de Andrade M et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am. J. Hum. Genet 2004 75 : 460 74.
5. Shaipanich T, McWilliams A, Lam S. Early detection and chemoprevention of lung cancer. Respirology 2006 11 : 366 72.
6. Kikuchi T, Carbone DP. Proteomics analysis in lung cancer: challenges and opportunities. Respirology 2007 12 : 22 8.
7. Bowman RV, Yang IA, Semmler AB, Fong KM. Epigenetics of lung cancer. Respirology 2006 11 : 355 65.
8. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat. Rev. Cancer 2004 4 : 707 17.
9. Belinsky SA, Klinge DM, Dekker JD, Smith MW, Bocklage TJ et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin. Cancer Res. 2005 11 : 6505 11.
10. Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 2006 66 : 3338 44.
11. Ahmed SM, Salgia R. Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology 2006 11 : 687 92.
12. Kato T, Nishio K. Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk. Respirology 2006 11 : 693 8.
13. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 2006 355 : 983 91.
14. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J. Clin. Oncol. 2006 24 : 4731 7.
15. Potti A, Dressman HK, Bild A, Riedel RF, Chan G et al. Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 2006 12 : 1294 300.
16. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N. Engl. J. Med. 2006 355 : 570 80.
17. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N. Engl. J. Med. 2007 356 : 11 20.
18. Raponi M, Zhang Y, Yu J, Chen G, Lee G et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res. 2006 66 : 7466 72.
19. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA 2006 103 : 2257 61.
20. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006 9 : 189 98.
21. Cooper S, Spiro SG. Small cell lung cancer: treatment review. Respirology 2006 11 : 241 8.
22. Govindan R, Page N, Morgensztern D, Read W, Tierney R et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J. Clin. Oncol. 2006 24 : 4539 44.
23. Ettinger DS, Aisner J. Changing face of small-cell lung cancer: real and artifact. J. Clin. Oncol. 2006 24 : 4526 7.
24. Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 2002 20 : 4434 9.
25. Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D et al. Phase II study of imatinib in patients with small cell lung cancer. Clin. Cancer Res. 2003 9 : 5880 7.
26. Johl J, Chanky K, Lara PN, Davies AM, Bold R et al. The proteasome inhibitor PS-341 (bortezomib) in platinum treated extensive small cell lung cancer (E-SCLC): a SWOG (0327) phase II trial. J. Clin. Oncol. 2005 23 : 632s.
27. Johnson DH. Management of small cell lung cancer: current state of the art. Chest 1999 116 : 525S 530.
28. Brahmer JR, Ettinger DS. Non-small cell lung cancer: adjuvant and neo-adjuvent chemotherapy. Respirology 2007 12 : 000 000.
29. Pisters KM, Le Chevalier T. Adjuvant chemotherapy in completely resected non-small-cell lung cancer. J. Clin. Oncol. 2005 23 : 3270 8.
30. Mehta M, Manon R. Are more aggressive therapies able to improve treatment of locally advanced non-small cell lung cancer: combined modality treatment? Semin. Oncol. 2005 32 : S25 34.
31. Sculier JP, Lafitte JJ, Berghmans T, Van Houtte P, Lecomte J et al. A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. Ann. Oncol. 2004 15 : 399 409.
32. Schild SE, Bogart JA. Innovations in the radiotherapy of non-small cell lung cancer. J. Thorac. Oncol. 2006 1 : 85 92.
33. Ready N. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer. Semin. Oncol. 2005 32 : S35 41.
34. Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin. Cancer. Res. 2005 11 : 795 805.
35. Abratt RP, Hart GJ. 10-year update on chemotherapy for non-small cell lung cancer. Ann. Oncol. 2006 17 : v33 6.
36. Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest 2006 130 : 1211 19.
37. Raez LE, Lilenbaum R. New developments in chemotherapy for advanced non-small cell lung cancer. Curr. Opin. Oncol. 2006 18 : 156 61.
38. D'Addario G, Pinitile M, Leighl NB, Feld R, Cerny T. et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis of the published literature. J. Clin. Oncol. 2005 23 : 2926 36.
39. Hirsch FR, Varella-Garcia M, Bunn PA Franklin WA, Dziadziuszko R et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol. 2006 24 : 5034 42.
40. Joshi VA, Kucherlapati R. Lung cancer genetics and pharmacogenomics. Cytogenet. Genome Res. 2006 115 : 298 302.
41. Suzuki R, Hasegawa Y, Baba K, Saka H, Saito H et al. A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer. Br. J. Cancer 2006 94 : 1599 603.
42. Yang CH, Shih JY, Chen KC, Yu CJ, Yang TY et al. Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer. Cancer 2006 107 : 1873 82.
43. Giaccone G, Gallegos Ruiz M, Le Chevalier T, Thatcher N, Smit E et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin. Cancer Res. 2006 12 : 6049 55.
44. Bunn PA Jr. Can a single pill replace doublet chemotherapy in first-line therapy of advanced non-small cell lung cancer? Clin. Cancer Res. 2006 12 : 5919 20.
45. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006 355 : 2542 50.
46. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 2005 23 : 2544 55.
47. Sandler A, Herbst R. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin. Cancer Res. 2006 12 : 4421s 25s.
48. Sockinski MA, Novello S, Sanchez JM, Brahmer J, Govindan R. Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer: preliminary results of a multicenter phase II trial. J. Clin. Oncol. 2006 24 : 364s.
49. Schiller JH, Flaherty KT, Redlinger M, Binger K, Eun J. Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: a phase I subset analysis. J. Clin. Oncol. 2006 24 : 412s.
50. Edelman MJ, Smith R, Hausner P, Doyle LA, Kalra K et al. Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 2005 23 : 5774 8.
51. Yen WC, Prudente RY, Corpuz MR, Negro-Vilar A, Lamph WW. A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br. J. Cancer 2006 94 : 654 60.
52. Montagut C, Rovira A, Albanell J. The proteasome: a novel target for anticancer therapy. Clin. Transplant. Oncol. 2006 8 : 313 17.
53. Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S et al. Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol. Cancer Ther. 2006 5 : 1585 92.
54. Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J et al. Autologous dendritic cell vaccines for non-small-cell lung cancer. J. Clin. Oncol. 2004 22 : 2808 15.
55. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001 414 : 105 11.
56. Jones RJ, Matsui W. Cancer stem cells: from bench to bedside. Biol. Blood Marrow Transplant. 2007 13S1 : 47 52.
57. Jones RJ, Matsui WH, Smith BD. Cancer stem cells: are we missing the target? J. Natl. Cancer Inst. 2004 96 : 583 5.
58. Dick JE, Lapidot T. Biology of normal and acute myeloid leukemia stem cells. Int. J. Hematol. 2005 82 : 389 96.
59. Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 2005 15 : 494 501.
60. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J et al. Characterization of clonogenic multiple myeloma cells. Blood 2004 103 : 2332 6.
61. Liu S, Dontu G, Wicha MS. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res. 2005 7 : 86 95.
62. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat. Rev. Cancer 2006 6 : 425 36.
63. Watkins DN, Berman DM, Baylin SB. Hedgehog signaling: progenitor phenotype in small-cell lung cancer. Cell Cycle 2003 2 : 196 8.
64. Daniel VC, Peacock CD, Watkins DN. Developmental signalling pathways in lung cancer. Respirology 2006 11 : 234 40.
65. Mackay J. Battlefield for the tobacco war. JAMA 1989 261 : 28 9.
66. Mackay J. Beyond the clouds - tobacco smoking in China. JAMA 1997 278 : 1531 2.
67. Mackay J. International aspects of US government tobacco bills. JAMA 1999 281 : 1849 50.